Physician profile
Rodney Berger
NPI 1316099849
$4,833.23
in general payments reported to CMS, 2019-2025
34 companies · $923 in 2025
The $923 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $88.76 · 2021: $583 · 2022: $892 · 2023: $532 · 2024: $1,122 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $711.70 | 2022-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $517.90 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $428.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $390.34 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.44 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $266.66 | 2022-2025 | Korlym |
| Abbott Laboratories | $257.99 | 2019-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $256.24 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $250.65 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $203.90 | 2024-2025 | |
| Orexo US, INC. | $187.56 | 2019-2025 | Zubsolv |
| Recordati_rare_diseases_inc. | $171.88 | 2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $127.88 | 2022 | |
| Mannkind Corporation | $96.79 | 2019-2023 | Afrezza |
| Glaxosmithkline, LLC. | $94.62 | 2023 | Arexvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $88.76 | 2019 | |
| Braeburn INC. | $71.71 | 2023 | Brixadi |
| Uswm, LLC | $67.69 | 2021-2022 | |
| Shire North American Group INC | $44.53 | 2019 | |
| Merck Sharp & Dohme LLC | $42.63 | 2021-2022 | |
| Pfizer INC. | $32.58 | 2025 | |
| Madrigal Pharmaceuticals | $26.79 | 2025 | Rezdiffra |
| Zealand Pharma US, INC. | $24.20 | 2022 | |
| Embecta Corp. | $24.16 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Xeris Pharmaceuticals, INC. | $20.07 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $18.20 | 2021 | |
| Gilead Sciences, INC. | $18.15 | 2020 | |
| Indivior INC. | $16.75 | 2021 | |
| Aroa Biosurgery Incorporated | $15.51 | 2025 | |
| Alfasigma USA, INC. | $14.75 | 2021 | |
| Dexcom, INC. | $14.07 | 2023 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $13.92 | 2024 | Stravix Pl, Grafix Xc, Oasis |
| Pear Therapeutics (US), INC. | $12.90 | 2021 | |
| Tandem Diabetes Care, INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.